DANIEL K SPIEGELMAN
CIK 1238403 · EVP, Chief Financial Officer · last filed 2026-06-29
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.26M
Companies
14
Total Filings
150
Lifetime Open-Market Net
-$34.49M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VTVT | Director | — | $31.08 | — | $0 | 3 | 2026-06-29 |
| MAZE | Director | — | $27.88 | — | $0 | 2 | 2026-06-10 |
| SPRB | Director | — | $41.60 | — | $0 | 7 | 2026-05-26 |
| KYTX | Director | 16,634 | $7.49 | $124.6K | $0 | 1 | 2025-06-02 |
| MYGN | Director | 32,917 | $5.32 | $175.1K | -$792.3K | 11 | 2024-06-07 |
| BMRN | EVP, Chief Financial Officer | 47,686 | $62.07 | $2.96M | -$30.78M | 59 | 2019-06-07 |
| Cascadian Therapeutics, Inc. (CASC) Delisted | Director | 21,006 | — | — | $0 | 4 | 2017-09-26 |
| Relypsa Inc (RLYP) Delisted | Director | 0 | — | — | -$19.6K | 4 | 2016-09-02 |
| Cascadian Therapeutics, Inc. (ONTY) Delisted | Director | 52,675 | — | — | $33.3K | 17 | 2015-09-28 |
| Anthera Pharmaceuticals Inc (ANTH) Delisted | Director | — | — | — | $0 | 5 | 2013-05-20 |
| AFFYMAX INC (AFFY) Delisted | Director | — | — | — | $0 | 6 | 2012-06-18 |
| OMER | Director | — | $11.28 | — | $0 | 3 | 2012-06-04 |
| Bio Green Med Solution, Inc. (CYCCP) Delisted | Director | — | $5.05 | — | $0 | 6 | 2012-05-24 |
| CV THERAPEUTICS INC (CVTX) Delisted | SVP, CFO | 74,458 | — | — | -$2.93M | 16 | 2009-04-17 |
Recent Filings · Page 2 of 15
150 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-27 | VTVT | Grant (A) | — | $0 | EDGAR |
| 2024-06-07 | MYGN | — | — | $0 | EDGAR |
| 2024-06-04 | MYGN | Notice (144) | −3,788 | -$83.5K | EDGAR |
| 2024-06-04 | MYGN | Sell (S) | −7,576 | -$167.0K | EDGAR |
| 2024-06-03 | MYGN | Notice (144) | −3,788 | -$83.5K | EDGAR |
| 2024-05-24 | SPRB | Grant (A) | — | $0 | EDGAR |
| 2023-06-02 | MYGN | Notice (144) | −8,638 | -$198.8K | EDGAR |
| 2023-06-02 | MYGN | Mixed | +6,513 | -$198.8K | EDGAR |
| 2023-05-26 | SPRB | Grant (A) | — | $0 | EDGAR |
| 2022-06-06 | MYGN | Sell (S) | −6,424 | -$123.7K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.